Recent Updates
Recently added Catalysts

Normal saline ,Control

Phase 3

Migraine Headache | Unknown | Neurology |The Cooper Companies, Inc.|Last Updated: Jul 15, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment50
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02933060Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine HeadachePHASE2/PHASE3 COMPLETED 50Jan 1, 2017Sep 1, 2017Jul 15, 2019 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Normal saline (1000 mL)OTHER -
ControlOTHER -
Unlock Study Design Details